2022.06.22 04:24

李氏大药厂 Teglutik 取得药品注册许可

李氏大药厂公布,Teglutik(利鲁唑口服混 悬 液) 已取得中国国家药品监督管理局的药品注册许可证。Teglutik 获认可用於延长肌萎缩性脊髓侧索硬化症患者的生命或延长其发展至需要机械通气支持的时间。

李氏大药厂 (00950.HK) 公布,Teglutik(利鲁唑口服混 悬 液) 已取得中国国家药品监督管理局的药品注册许可证。Teglutik 获认可用於延长肌萎缩性脊髓侧索硬化症患者的生命或延长其发展至需要机械通气支持的时间。Teglutik 为 Italfarmaco 的引进产品,获授独家分销权,於中国、香港、澳门及台湾开发及商业化。(de/d)
The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: editorial@longbridge.global